Lantheus (LNTH) vs Oruka Therapeutics (ORKA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oruka Therapeutics (ORKA) has outperformed Lantheus (LNTH) over the past year, gaining 286.5% versus a gain of 93.2%. Over five years, LNTH leads with a +330.7% price change compared with +137.5% for ORKA. Lantheus is the larger company by market cap ($6.54 billion vs $5.26 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LNTH | ORKA |
|---|---|---|
| Share price | $100.18 | $79.50 |
| Market cap | $6.54B | $5.26B |
| 1-day change | +0.23% | -0.85% |
| YTD return | +50.53% | +162.29% |
| 1-year return | +93.25% | +286.49% |
| 5-year return | +330.70% | +137.46% |
| P/E ratio (TTM) | 24.26 | — |
| Forward P/E | 15.71 | — |
| EPS (TTM) | $4.13 | $-2.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54B | — |
| Revenue growth (YoY) | +0.50% | — |
| Net income (latest FY) | $233.56M | $-105.43M |
| Gross margin | 61.10% | — |
| Operating margin | 20.16% | — |
| Net margin | 15.15% | — |
| 52-week high | $111.86 | $115.52 |
| 52-week low | $50.16 | $21.66 |
| Distance from 52-week high | -10.44% | -31.18% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +7.55% | +94.97% |
| Average volume | 1.32M | 886.21K |
| Shares outstanding | 65.30M | 66.21M |
| Employees | 1,193 | 68 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORKA has outperformed LNTH by 193.2 percentage points over the past year.
About Lantheus
LNTH stock →Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 1,193 employees
About Oruka Therapeutics
ORKA stock →Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 68 employees
LNTH vs ORKA FAQ
Which is bigger, Lantheus or Oruka Therapeutics?
Lantheus (LNTH) is larger, with a market capitalization of $6.54B compared with $5.26B for Oruka Therapeutics (ORKA).
Which stock has performed better over the past year, LNTH or ORKA?
ORKA returned +286.49% over the past 12 months, compared with +93.25% for LNTH (price return, excluding dividends). Past performance does not predict future results.
Are Lantheus and Oruka Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.